Loading…
Based on limited metadata, this FDA Warning Letter issued to Aurobindo Pharma Limited on June 20, 2019, concerns drug manufacturing or quality compliance issues, though the specific violations cannot be detailed without the full letter text. Aurobindo Pharma Limited is a pharmaceutical manufacturer subject to FDA oversight for drug products. The warning was issued by the FDA's drug regulatory division, but without access to the complete letter, the precise nature and scope of the violations remain undetermined.